For three consecutive years! Medicilon has been honored with the "Top Ten Drug Innovation Service Institutions of the Year" award at the 4th Pharmaceutical Innovation Awards.

On June 20^t^h, the 4^th Pharmaceutical Innovation Awards ceremony, organized by the Securities Times under People's Daily, was unveiled in Shanghai. Medicilon was honored with the "Top Ten Drug Innovation Service Institutions of the Year" at the 4^thPharmaceutical Innovation Awards for its innovative capabilities and service quality in the field of biopharmaceutical preclinical R&D services.

This marks the third consecutive year that Medicilon has won this prestigious award. This achievement not only serves as a profound recognition of its two decades of continuous contributions to drug development but also stands as the best testament to its spirit of innovation.

About Pharmaceutical Innovation Awards

The "Pharmaceutical Innovation Award" is a highly influential event within the industry, organized by Securities Times, an authoritative financial and securities media outlet under the People's Daily. The award aims to recognize companies and individuals who have made outstanding achievements in the field of pharmaceutical innovation, thereby promoting the enhancement of China's pharmaceutical innovation capabilities and industrial development. The selection process strictly adheres to principles of scientific rigor, fairness, and impartiality. It utilizes the "People's Financial • Innovative Drug Index" database and company application materials, and involves multiple stages such as expert reviews and public voting, ensuring that each awarded project, company, and individual truly deserves the recognition.

As one of the few one-stop preclinical research service platforms for biopharmaceuticals in China, Medicilon has a long-standing tradition of innovation. Since its establishment, Medicilon has always regarded innovation as its core driving force, continually creating and improving its service platform. This has enabled seamless integration from drug discovery and pharmaceutical research to preclinical research. Moreover, Medicilon has built cutting-edge research service platforms in advanced fields such as antibodies, peptides, ADCs, PROTACs, mRNA vaccines, small nucleic acid drugs, and cell and gene therapy (CGT).

With twenty years of innovative accumulation and rich experience, Medicilon precisely empowers its clients, helping them achieve numerous remarkable successes in the pharmaceutical field. As of the end of April 2024, Medicilon has been involved in the research and development of 480 new drug and generic drug projects that have received approvals from CFDA/NMPA, US FDA, and Australia's TGA to enter clinical trials. Among these, Medicilon has successfully assisted in the development of 34 antibodies (including monoclonal, bispecific, and trispecific antibodies), 24 ADC drugs, 8 GLP-1 hypoglycemic drugs, and 3 traditional Chinese medicines approved for clinical use. The successful development of these drugs not only provides patients with more treatment options but also injects strong momentum into the innovative development of the entire pharmaceutical industry. In addition, Medicilon actively serves over 50 ADC clients, more than 40 small nucleic acid clients, and over 3 PROTAC-related clients, providing them with professional technical support and solutions, earning widespread acclaim.

Medicilon's winning of the "Pharmaceutical Innovation Award" is a high recognition of its innovative spirit and professional strength. It also serves as a motivation and encouragement for its continuous efforts in promoting innovation and development within the pharmaceutical industry. This honor will inspire Medicilon to continue adhering to its innovation principles, increasing investment in research and development, strengthening technological innovation, and enhancing talent development. This commitment will continuously drive innovation and promote the advancement of the pharmaceutical industry. At the same time, Medicilon will also empower its clients with even more professional and efficient service quality, thereby contributing to the thriving development of the pharmaceutical industry!

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客